UK Nod For Pfizer’s COVID-19 Oral Treatment
Pfizer Aims For Early 2022 To Deliver First Treatment Courses To Great Britain
Pfizer’s Paxlovid is the second take-at-home COVID-19 treatment approved for use in the UK.
You may also be interested in...
The European Medicines Agency’s assessment of the oral antiviral combination was conducted under the OPEN Initiative, which involves information sharing among international regulators.
Coronavirus Notebook: Pfizer Files Paxlovid In EU, France Updates Treatment Advice As Omicron Proliferates
NRx Pharmaceuticals has again filed for a US emergency use authorization for aviptadil, this time for critically ill patients with no other options. The UK has said that there is currently no need to give a second booster vaccine.
US regulators have granted emergency authorization to the antiviral molnupiravir but only for use when "alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."